Cannabis Freedom Index
← History

Medical 🇦🇺 Australia

Australia legalises medical cannabis

From 29 October 2016, the Narcotic Drugs Act 1967 allowed the Commonwealth to license the cultivation and manufacture of cannabis for medical and scientific use, creating the first lawful domestic supply. Parliament passed the amendment in February 2016, but the licensing provisions commenced only on 29 October after no proclamation was made. Patients still needed TGA approval through the Special Access Scheme or an authorised prescriber; the Act did not create a patient register or a pharmacy product.[1][2]

Index score

1922

+3 points

The story · written by deepseek-v4.1-flash,

On 29 October 2016 the Commonwealth’s licensing provisions for medical cannabis commenced. The Narcotic Drugs Act 1967 now allowed the federal government to license the cultivation and manufacture of cannabis for medical and scientific use, creating Australia’s first lawful domestic supply.[1]

A supply-side reform

Parliament passed the Narcotic Drugs Amendment Act in February 2016, but the licensing provisions did not commence until 29 October, after no proclamation was made. The Act did not legalise possession for patients or create a pharmacy product. It set up a licensing system for growers and manufacturers, leaving the patient route to the therapeutic goods system.[1]

The patient route

Patients still needed approval through the Therapeutic Goods Administration’s Special Access Scheme or an authorised prescriber. Most products were unapproved therapeutic goods: they had not been assessed by the TGA for safety or efficacy, and patients generally paid privately.[2] The Act did not create a patient register, a national product list or a subsidised supply channel.

That gap explains the shape of the market that followed. Telehealth clinics and private prescribers expanded faster than the licensed domestic industry, and regulators later began reviewing closed-loop models where the prescriber, referral and pharmacy were part of one business.[2]

A narrow legalisation

The 2016 Act is best understood as a supply-side legalisation. It made licensed production possible and gave doctors a lawful route to prescribe, but it did not make cannabis a normal medicine or a retail product. The access score moved because a patient route existed; the possession and supply offences stayed.[1][2]

The licensing date is often confused with the February assent. The Act was passed in February, but the provisions that mattered for cultivation and manufacture commenced on 29 October 2016.[1]

The change is traced in the 2016 entry, and the current medical and possession rules are in Australia’s profile.

Score by segment 0 to 10

  1. Possession · 25%2 2
  2. Personal cultivation · 25%2 2
  3. Punishment & enforcement · 20%3 3
  4. Sharing & gifting · 10%1 1
  5. Consumption · 10%2 2
  6. Legal access · 10%0 3+3

The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Australia's current scores.

References

  1. Australia — Narcotic Drugs Amendment Act 2016 (Cth)Section 2 and Schedule 1; assent 29 February 2016, Schedule 1 commenced 29 October 2016.archived
  2. Therapeutic Goods Administration — Medicinal cannabisSpecial Access Scheme and Authorised Prescriber routes; unapproved products.archived

Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.

    ↑↓ to move, ↵ to open.